Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7001261 | 1.00 | EGLN2 (0.41) | EGLN2TRPA1ARIDH1TTK | |
| SCHEMBL29863376 | 0.85 | TRPA1 (0.45) | EGLN2TRPA1ARTTKMAPKAPK2 | |
| SCHEMBL24726507 | 0.85 | TRPA1 (0.45) | EGLN2TRPA1ARTTKMAPKAPK2 | |
| SCHEMBL7310686 | 0.84 | MAPKAPK2 (0.40) | EGLN2TRPA1ARTTKMAPKAPK2 | |
| SCHEMBL6469040 | 0.81 | LCK (0.46) | LCK | |
| SCHEMBL7106252 | 0.81 | TRPA1 (0.39) | EGLN2TRPA1ARTTKMAPKAPK2 | |
| SCHEMBL7110984 | 0.80 | NLRP3 (0.42) | EGLN2ARMAPKAPK2AAK1ALDH1A1 | |
| SCHEMBL21584977 | 0.80 | LCK (0.42) | LCK | |
| SCHEMBL31709542 | 0.80 | SYK (0.38) | EGLN2TTKLCKMAPKAPK2AAK1 | |
| SCHEMBL15142858 | 0.80 | SYK (0.47) | EGLN2ARLCKMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626891-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | Omeros Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024118840-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | OMEROS CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | EGLN2 2485/4885TRPA1 4609/4885AR 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.